Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHT phase IIb/III trial of efsubaglutide alfa in overweight and obesity
CTR20250720Phase 3Active
- Sponsor
- Yinnuo Pharmaceutical
- Start
- Mar 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of efsubaglutide alfa in obesity, Overweight, sponsored by Yinnuo Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
efsubaglutide alfa
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20250720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250720.